The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
Open accessAbstract
Importance: Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies. Objective: To characterize ARIA in participants treated with donanemab. Design, Setting, and Participants: These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-controlled trials and the open-label addendum aged 60 to 85 years with early symptomatic Alzheimer disease and elevated amyloid levels were included. The placebo-controlled trials, but not the addendum, had tau inclusion criteria. Interventions: Placebo-controlled trial participants were randomized 1:1 to receive placebo or donanemab, and all open-label participants received donanemab. Donanemab was administered every 4 weeks for up to 72 weeks. Main Outcomes and Measures: The primary outcomes were the frequency, radiographic severity, seriousness, symptoms, timing relative to donanemab treatment, and risk factors for ARIA. Results: Across 3030 total participants (placebo-controlled trials: 999 placebo participants, 984 donanemab participants; open-label addendum: 1047 donanemab participants), mean (SD) age was approximately 73.7 (6.0) years and 1684 participants (55.6%) were female. Frequencies of ARIA–edema/effusions (ARIA-E) and ARIA–microhemorrhages and hemosiderin deposition (ARIA-H) were higher with donanemab (24.4% and 31.3% in placebo-controlled trials, respectively; 19.8% and 27.2% in open-label addendum, respectively) than with placebo (1.9% and 13.0%, respectively). ARIA-E was mostly mild or moderate in severity. Serious ARIA-E was reported in 1.5% and symptomatic ARIA-E in 5.8% of donanemab-treated participants in the placebo-controlled trials. Symptoms most frequently reported with ARIA-E were headache and confusional state. In 58.3% of donanemab-treated participants with ARIA-E, the first event occurred by the third infusion (approximately month 3). Risk analysis demonstrated independent associations between ARIA-E and 6 baseline variables, including increased risk with APOE ε4 allele number, greater number of microhemorrhages, presence of cortical superficial siderosis, higher amyloid plaque, and elevated mean arterial pressure, and decreased risk with antihypertensive use. Conclusions and Relevance: ARIA is an adverse event associated with donanemab treatment that requires safety monitoring. Individual ARIA risk can be assessed by APOE ε4 status and baseline imaging findings. Trial Registrations: ClinicalTrials.gov Identifiers: NCT03367403 and NCT04437511
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Self-citationCerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Self-citationCharidimou, A., Boulouis, G., Frosch, M. P., Baron, J.-C., Pasi, M., Albucher, J. F., Banerjee, G., Barbato, C., Bonneville, F., Brandner, S., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00208-3 · Cited by 723
Self-citationSalloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619
Self-citationAmyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
Two phase 3 trials of gantenerumab in early Alzheimer's disease
Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., Wojtowicz, J., Blennow, K., Bittner, T., Black, S. E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304430 · Cited by 314
Self-citationAmyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5205 · Cited by 189
Cited by
Donanemab: Appropriate use recommendations
Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., et al. (2025) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100150 · Cited by 278
Self-citationNonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35
Filippi, M., Cecchetti, G., Spinelli, E. G., Ghirelli, A., Rugarli, G., Pisano, S., Canu, E., & Agosta, F. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101609 · Cited by 14
Metadata
- Authors
- Zimmer, J. A., Ardayfio, P., Wang, H., Khanna, R., Evans, C. D., Lu, M., Sparks, J., Andersen, S., Lauzon, S., Nery, E. S. M., Battioui, C., Engle, S. E., Biffi, A., Svaldi, D., Salloway, S., Greenberg, S. M., Sperling, R. A., Mintun, M., Brooks, D. A., & Sims, J. R.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2025-05-01
- Volume
- 82
- Issue
- 5
- Pages
- 461
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W4408290084
- Cited by
- 168
- References
- 9
- FWCI
- 90.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. https://app.cochat.ai/papers/10.1001/jamaneurol.2025.0065
- The paper
- Zimmer, J. A., Ardayfio, P., Wang, H., Khanna, R., Evans, C. D., Lu, M., Sparks, J., Andersen, S., Lauzon, S., Nery, E. S. M., Battioui, C., Engle, S. E., Biffi, A., Svaldi, D., Salloway, S., Greenberg, S. M., Sperling, R. A., Mintun, M., Brooks, D. A., & Sims, J. R. (2025). Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2025.0065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.